Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Global Matrix Group (NASDAQ: GMGI) Appoints Mr William Scott to Build on Success and Accelerate Growth
-
EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients
-
Bowman Acquires RPT Alliance, Broadens Energy Engineering to Include Utility-Scale Power Generation for Data Centers and Industrial Facilities
-
Pulsar Helium Reports Pressurised Gas Encounter at Jetstream #5 and Down-Hole Testing Conducted at Jetstream #3 and #4
-
Periodic announcement on the acquisition of the Bank‘s own shares and its results (week 1)
-
ING reports outcome of 2025 EU-wide transparency exercise
-
Scatec signs equity partnership agreements for Obelisk in Egypt
-
Extension of charter agreement of the cruise ferry Silja Europa
-
Contract with Czechoslovak Group and positive investor feedback at the WOOD & Co Conference
-
Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit
-
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL
-
NBPE Announces Transaction in Own Shares
-
OSB GROUP PLC - Transaction in Own Shares
-
Transaction in Own Shares
-
SHELL PLC THIRD QUARTER 2025 EURO AND GBP EQUIVALENT DIVIDEND PAYMENTS
-
Initial admission to the Official List
-
AI Agents to Power 1,000% More Customer Interactions for Enterprises Globally by 2027
-
Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025
-
ASH 2025: Cellectis Presents Development Plan to Further Enhance High Response Rate Observed for Eti-cel in r/r NHL
-
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
-
Sampo plc’s share buybacks 5 December 2025
-
L’ORÉAL GROUPE TO REINFORCE ITS STRATEGIC INVESTMENT IN GALDERMA WITH AN ADDITIONAL 10% BRINGING ITS TOTAL PARTICIPATION TO 20%
-
Start of Day Message
-
BNP PARIBAS : BNP PARIBAS GROUP SELLS ITS STAKE IN AG INSURANCE AND FORMALISES LONG TERM PARTNERSHIP WITH AGEAS
-
Ageas to take full ownership of AG Insurance and formalise long term partnership with BNP Paribas
-
YAS Healthcare signs contract for a Proteus®ONE solution, the first proton therapy system to be installed in Dubai, UAE
-
NOTICE TO DISREGARD -- ICARO Media Group
-
SED Initta and Intel Deepen Strategic Partnership to Accelerate AI-Driven Retail Transformation
-
HVAC Expert Ben Fleck of Gretna Advises Homeowners to Change Air Filters Regularly in HelloNation
-
Pest Control Expert Steven Moore of Port Washington Shares The Top 4 Household Pests for HelloNation
-
Collision Repair Expert Andy Spence of Jackson, TN, Explains Why Certified Collision Repair Matters for HelloNation
-
Retail Expert Melissa Skelton Shares Insights on Custom vs. Commercial Easter Gifts in New HelloNation Feature
-
Laser Hair Removal Expert Dr. Terese Thomas, MD Explains Sublative Radiofrequency vs Facial in HelloNation
-
Marine Transport Expert Jon Arrigoni of Arrigoni Marine Movers Warns Boat Owners About Insurance Gaps in HelloNation
-
Cochin Shipyard to build next-generation electric TRAnsverse tugs for Svitzer
-
HeroFlow Announces Expansion of Access to “The AI Employee,” the 24/7 Virtual Receptionist That Never Calls In Sick
-
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The FX Super One First Pre-Production Vehicles Roll-off Ceremony is Scheduled for December 21 at the Company’s Hanford, CA Fac
-
The Ohio State University’s Caleb Downs Named Winner of Lott IMPACT Trophy Presented by Allied Universal
-
OPay Appoints Former Citigroup Managing Director James Perry as CFO
-
ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances
-
Skyline Digital Marketing Introduces Proprietary Skyline Methodology to Strengthen Data-Driven Business Growth
-
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List and Inclusion in the First Commercial Insurance Drug List in China
-
Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025
-
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
-
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Am
-
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025
-
Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For
-
Lime & Lemon Apex Redefines the Dining Scene with an Experience the Triangle Was Waiting For
-
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
-
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
